XLV240927P157500
- 2.57
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Lilly Gets Traditional FDA Approval for Retevmo for Thyroid Cancer
J&J, Legend Report Carvykti Cut Death Risk by 45% in Multiple Myeloma Study
(ABBV) - Analyzing AbbVie's Short Interest
J&J Releases Encouraging Data on Talvey Combination Therapies
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Merck Snaps Six Straight Sessions of Losses
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
Amgen Analyst Ratings
Acadia Healthcare's Stock Plunges After Government Probe Into Patient Care
Cantor Highly Bullish on Amgen Obesity Drug, Starts Coverage at Overweight
Summit Therapeutics Downgraded at Citi on Valuation
Palo Alto, Delta Air, PayPal And More On CNBC's 'Final Trades'
Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple...
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
J&J Snaps Six Straight Sessions of Losses
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
Abbott Laboratories Analyst Ratings
BioAge Stock Rallies 29% Following Upsized $198M IPO